Although other immune cells, such as CD11b+ myeloid cells, F4/80+ macrophages, Ly6G+ neutrophils, αSMA+ fibroblasts, and CD31+ blood vessel endothelial cells, did not change in response to anti-PD-1 treatment (Figure 2E and 2F), we observed enrichment with large amounts of neutrophils, macrophages, and fibroblasts in the tumor margin in the 2 groups (Figure 2F). This evidence concerns the gene ITGAM and neoplasm.